Tonix Pharmaceuticals Holding Corp. Common Stock TNXP
i
Market dataready · fetched 2026-11-12T03:18:55.252Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-06-17
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:53:57.779518809Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T03:18:53.766619+00:00
Tonix Pharmaceuticals Holding Corp. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 5.17 | 159.3% | 35.7% | |||
| 40Δ | 5.57 | 150.3% | 31.1% | |||
| 45Δ | 6.68 | 116.7% | 93.6% | 5.96 | 141.3% | 26.4% |
| 50Δ | 6.12 | 120.2% | 82.5% | 6.36 | 132.3% | 21.8% |
| 55Δ | 5.56 | 123.7% | 71.3% | 6.75 | 123.3% | 17.2% |
| 60Δ | 4.99 | 127.2% | 60.3% | 7.15 | 114.2% | 12.5% |
| 65Δ | 4.46 | 132.7% | 52.2% | 7.65 | 106.6% | 8.1% |
| 70Δ | 3.94 | 138.3% | 44.1% | 9.00 | 109.9% | 4.9% |
| 75Δ | 3.41 | 143.8% | 36.0% | |||
| 80Δ | 2.88 | 149.3% | 27.9% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.17
- IV
- 159.3%
- B/E move
- 35.7%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.57
- IV
- 150.3%
- B/E move
- 31.1%
45Δ
- Pseudo strike
- 6.68
- IV
- 116.7%
- B/E move
- 93.6%
- Pseudo strike
- 5.96
- IV
- 141.3%
- B/E move
- 26.4%
50Δ
- Pseudo strike
- 6.12
- IV
- 120.2%
- B/E move
- 82.5%
- Pseudo strike
- 6.36
- IV
- 132.3%
- B/E move
- 21.8%
55Δ
- Pseudo strike
- 5.56
- IV
- 123.7%
- B/E move
- 71.3%
- Pseudo strike
- 6.75
- IV
- 123.3%
- B/E move
- 17.2%
60Δ
- Pseudo strike
- 4.99
- IV
- 127.2%
- B/E move
- 60.3%
- Pseudo strike
- 7.15
- IV
- 114.2%
- B/E move
- 12.5%
65Δ
- Pseudo strike
- 4.46
- IV
- 132.7%
- B/E move
- 52.2%
- Pseudo strike
- 7.65
- IV
- 106.6%
- B/E move
- 8.1%
70Δ
- Pseudo strike
- 3.94
- IV
- 138.3%
- B/E move
- 44.1%
- Pseudo strike
- 9.00
- IV
- 109.9%
- B/E move
- 4.9%
75Δ
- Pseudo strike
- 3.41
- IV
- 143.8%
- B/E move
- 36.0%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 2.88
- IV
- 149.3%
- B/E move
- 27.9%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 219.65% |
Biotechnology
TNYA
Tenaya Therapeutics Inc. is a pioneering clinical-stage biotechnology firm that is revolutionizing the treatment of heart disease through its proprietary engineered heart cell…
More →TRAX
First Tracks Biotherapeutics (Ticker: TRAX) is a forward-thinking biotechnology company focused on developing targeted therapeutics for chronic diseases, utilizing advanced…
More →TRDA
Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by significant unmet…
More →TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of Haduvio to treat serious neurology-mediated…
More →TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on the development and commercialization of adeno-associated virus-based gene therapies for the treatment of monogenic…
More →TTRX
Description unavailable
More →